Ayisha Sharma is a News Reporter at Endpoints News. She focuses on the UK and Europe biopharma space, with a particular interest in psychiatric drug R&D, and covers topics related to pharmaceuticals, healthcare systems, and mental health. Ayisha has been featured in prominent publications including Citeline, The Guardian, and NewsBreak.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Ayisha Sharma's coverage is primarily focused on the healthcare and pharmaceutical industry, with a strong emphasis on corporate developments, clinical trials, and regulatory actions. Her articles largely feature press releases and cite data from private sector announcements. Therefore, she may be particularly interested in pitches that provide exclusive access to breaking news within the pharmaceutical or biotech industries.
Given her focus on specific companies' activities such as licensing deals, FDA warnings, bankruptcies, and legal disputes within the healthcare sector; experts who have insights into these areas would likely capture her attention.
Ayisha's reporting does not seem to have a geographic focus but rather covers global developments in the pharmaceutical and biotech sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ayisha Sharma
Novartis eyes Alzheimer's and Parkinson's as it looks to expand the AOC platform acquired in its $12 billion Avidity Biosciences buyout.
By: Ayisha Sharma
Astellas Pharma is aiming to double sales for its five key medicines, including Pfizer-partnered bladder cancer drug Padcev, through fiscal year 2030 under a new …
By: Ayisha Sharma
GSK has shared detailed results from a pair of late-stage trials testing a chronic hepatitis B treatment originally developed by Ionis Pharmaceuticals, with regulatory reviews …
By: Ayisha Sharma
AbbVie said the FDA has approved an antibody-drug conjugate it obtained as a part of its $10.1 billion buyout of ImmunoGen for …
By: Ayisha Sharma
On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a portfolio of 12 early-stage antibody-drug conjugates and multi-specific antibodies in a deal that could be worth up to $10.5 billion.
By: Ayisha Sharma
Customise Consent Preferences We use cookies to help you navigate efficiently and perform certain functions.
By: Ayisha Sharma
Turn Therapeutics' topical GX-03 hit EASI-50 in 93% of eczema patients at four weeks.
Barcelona-based Ona Therapeutics has raised $86.6 million in a Series B round to advance two ADC candidates into the clinic.
By: Ayisha Sharma
Backlash is brewing against a sweeping overhaul of Germany’s health insurance system as Eli Lilly and Boehringer Ingelheim slash investment in the country.
By: Ayisha Sharma
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
